Home > Pressemitteilung: Promising Active Ingredient for Lupus ...

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of lupus nephritis.

New research reveals disturbing nightmares and hallucinations may serve as early warning signs of lupus, potentially helping patients receive treatment sooner.

HealthDay News — For patients with systemic lupus erythematosus (SLE) and pericarditis, recurrence of pericarditis occurs in more than 20 percent of patients and associated factors include younger age ...

Living with lupus can be overwhelming, says columnist Candace Semien, but it's important to hold tight and fight for yourself ...

From eczema to allergic reactions to bug bites, here’s what common skin rashes look like in photos, and the symptoms that can help you I.D. the condition.

Chimeric antigen receptor T-cell therapy improves not only lupus disease activity but also other related conditions that ...

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA) for ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License ...

Patients whose autoimmune disorders such as lupus were initially dismissed by doctors as psychosomatic show long-lasting ...

The etiology of these rashes can be divided into those that are specific to lupus and those that can occur ... (Plaquenil ®) are commonly used to treat SCLE. Steroids and cytotoxic agents may ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...